Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ADEM: distinct disease or part of the MS spectrum?
Hartung HP, Grossman RI. Hartung HP, et al. Neurology. 2001 May 22;56(10):1257-60. doi: 10.1212/wnl.56.10.1257. Neurology. 2001. PMID: 11376169 Review. No abstract available.
Chemotherapy-induced peripheral neuropathy.
Quasthoff S, Hartung HP. Quasthoff S, et al. J Neurol. 2002 Jan;249(1):9-17. doi: 10.1007/pl00007853. J Neurol. 2002. PMID: 11954874 Review.
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: hartung hp. Brain. 2024 Dec 21:awae409. doi: 10.1093/brain/awae409. Online ahead of print. Brain. 2024. PMID: 39707906
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Hartung HP, Benedict RHB, Berger T, Bermel RA, Brochet B, Carroll WM, Freedman MS, Holmøy T, Karabudak R, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Wuerfel J, Clinch S, Kadner K, Kuenzel T, Kulyk I, Raposo C, Thanei GA, Killestein J. Hartung HP, et al. Neurology. 2024 Dec 24;103(12):e210049. doi: 10.1212/WNL.0000000000210049. Epub 2024 Dec 3. Neurology. 2024. PMID: 39626127 Clinical Trial.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S. Meuth SG, et al. Among authors: hartung hp. Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143. Online ahead of print. Ann Neurol. 2024. PMID: 39582359
1,340 results